In clinical studies, our novel antisense drugs have been well-tolerated and have met efficacy endpoints. Our most advanced clinical program is in cardiovascular restenosis. We have completed Phase II trials evaluating our antisense drug, Resten-NG, and expect to begin a Phase III study for this indication.

We also expect to begin other clinical trials this year, evaluating our drug candidates in patients with certain viral infectious diseases, bladder cancer and polycystic kidney disease. Our NeuGene drug candidates have shown antiviral activity in preclinical and field trials against a broad group of RNA viruses, including hepatitis C virus, West Nile virus, SARS coronavirus, Dengue fever virus and Ebola virus.

AVI has evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer. We continue to discuss strategic partnerships for Phase III trials and commercialization of Avicine.